Annovis Bio reports Q3 net loss of $0.37/share; Phase 3 AD trial fully activated at 84 sites

Annovis Bio, Inc.

2025-Q3 EPS reported -$1.01

Cash and equivalents $15.3M as of Sep 30, 2025; plus $9.4M in Oct offerings.
Phase 3 early AD study (NCT06709014) fully activated; first patients completed 6-month treatment.
Biomarker results from Phase 2/3 showed reductions in neuroinflammation and neurodegeneration markers.
Appointed Mark Guerin as CFO; all patents transferred to new crystal form of buntanetap (IP through 2046).
R&D expense $6.3M (up from $2.7M YoY); net loss $0.37 per share (vs $0.97).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.